• Born in Bologna 16.08.1942
• M.D. degree 1966, University of Bologna
• Postgraduate degree in Hematology, 1969, University of Modena
• Research fellow, Rigshospitalet, University of Copenhagen, 1970
• Fellow, resident and senior resident at the Institute of Hematology "L. and A. Seràgnoli", S. Orsola University Hospital, Bologna, 1971-1980
• Professor of Cancer Chemotherapy, University of Chieti, 1980
• Professor of Hematology, University of Trieste, 1981-1986
• Professor of Hematology, University of Udine, from 1987 to 2000
• "Head, Division of Hematology and Bone Marrow Transplantation, Udine University Hospital, from 1989 to 2000
• Professor of Hematology, University of Bologna, from 2000
• Head, Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", S.Orsola University Hospital, Bologna, from 2000 to 2007, and Department of Hematology and Oncology "L. and A. Seràgnoli" from 2008 .
• President, Italian Society of Experimental Hematology, 1994-1995
• President, Italian Society of Hematology, 2002-2003
• Chairman, GIMEMA CML Working Party (formerly Italian Coop. Study Group on Chronic Myeloid Leukemia), from 1989
• Member, Working Package 4 Chronic Myeloid Leukemia, European LeukemiaNet
• Vice-Dean, Faculty of Medicine and Surgery, University of Bologna, from 2001 to 2007
• Clinical interest: chronic myeloid leukemia, acute leukemia, chemotherapy, stem cell transplantation
• Research interest: cell kinetics, stem cells, multidrug resistance, molecular pathogenesis of leukemia

Andrey Zaritskey

Saint-Petersburg, Russia

Andrey Zaritskey is Professor of hematology, Director of Institute of Oncohematology of Federal center of Heart, Blood and Endocrinology and lecture of Saint-Petersburg Pavlov state Medical University. He was graduated and post-graduated in Saint-Petersburg Pavlov State Medical University during 1967-1978 years. He has published more than 197 articles/abstracts in national and international journals. His scientific interest is the study of chronic myeloid leukemia and chronic lymphoproliferative neoplasms (chronic lymphocytic leukemia and Non-Hodgkin lymphomas), mesenchymal cell-haematopoietic cell interactions. He has been participating in nilotinib, dasatinib and bosutinib phase II and III international studies. He is one of the leaders in chronic myeloid and lymphatic leukemia in Russia, and deputy-chair of the scientific board of Russian Experts in chronic
myeloid leukemia.